Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PT586
- Development stage
- Preclinical
- Lead developer
- Phanes Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PT586 is a bispecific antibody (bsAb) currently in IND-enabling development by Phanes Therapeutics for the treatment of glioblastoma (GBM). The molecule is engineered to simultaneously target a tumor-associated antigen (TAA) and CD47. CD47 is a cell surface protein that functions as a "don't eat me" signal by interacting with SIRPα on macrophages, thereby inhibiting phagocytosis. By dual-targeting, PT586 is intended to enhance the selective binding to tumor cells over healthy cells (such as erythrocytes), potentially improving the safety profile compared to monospecific CD47 inhibitors while promoting the immune-mediated destruction of glioblastoma cells.
02
Targets
CD47 (Cluster of Differentiation 47)MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on PT586.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PT586.